Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized tobramycin versus nebulized colistimethate sodium for acute exacerbation of bronchiectasis with Pseudomonas aeruginosa infection
ChiCTR2300068587Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tobramycin and colistimethate sodium in bronchiectasis and Pseudomonal infection (2 arms), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Change in CPIS score from baseline after 5 days of treatment. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
tobramycincolistimethate sodium
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on ChiCTR2300068587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068587.